Free Trial
The Rate Lock Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 a Year
Claim MarketBeat All Access Sale Promotion
NASDAQ:ARVN

Arvinas Q3 2026 Earnings Date & Estimates

Arvinas logo
$7.86 -0.04 (-0.52%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Arvinas is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arvinas in Q3 2026

Arvinas is expected to post earnings of -$0.8672 per share on revenue of $16.82 million. In the same quarter a year earlier Arvinas reported -$0.48 per share on revenue of $41.90 million. Arvinas last reported on August 4, 2026, posting $2.58 per share and beating the -$0.3741 consensus estimate. Arvinas has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.8672
Expected Revenue
$16.82 million
Prior-Year EPS
-$0.48
Prior-Year Revenue
$41.90 million
Expected Revenue Growth
-59.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$2.58 (Beat by +$2.9541)
Last Quarter Revenue
$249.70 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Arvinas Q3 2026 Earnings FAQ

Arvinas (NASDAQ:ARVN) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Arvinas' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arvinas to post earnings of -$0.8672 per share for Q3 2026.

The consensus revenue estimate for Arvinas is $16.82 million for Q3 2026.

Arvinas Earnings Headlines

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
October 27 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3389585/0/en/arvinas-announces-return-of-early-career-researcher-award-to-recognize-innovation-in-targeted-protein-degradation.html
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
October 27 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3388821/0/en/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026.html
Federal Reserve’s Disturbing Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
October 30 at 1:00 AM  |  Weiss Ratings (Ad)
Critical Comparison: Valneva (NASDAQ:VALN) and Arvinas (NASDAQ:ARVN)
October 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31158142
Arvinas, Inc. (ARVN) Analyst Insights, Price Targets & Recommendations - Yahoo Finance
October 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ARVN/analyst-insights/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
October 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BHC/pressreleases/5341770/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bausch-health-companies-bhc-arvinas-holding-company-arvn-and-ovid-therapeutics-ovid/
See More Arvinas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email.

About Arvinas

Arvinas (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins. The company has also pursued programs in additional disease areas, including neurological and immunological conditions.

Founded in 2013 by Yale University scientist Craig Crews, a pioneer in targeted protein degradation, Arvinas is headquartered in New Haven, Connecticut. The company collaborates with pharmaceutical partners to advance and commercialize selected programs, including a collaboration with Pfizer related to vepdegestrant. Arvinas is led by President and Chief Executive Officer John Houston and serves global markets through its research, development and strategic partnership activities.

View Arvinas Profile
Earnings Tools